Maravai LifeSciences (MRVI) recently moved above the average analyst 12-month target of $6.90, trading at about $7.22/share. This suggests the stock has run to (and modestly exceeded) analysts’ consensus valuation level, with limited additional fundamental detail provided in the excerpt.
Maravai LifeSciences (MRVI) recently moved above the average analyst 12-month target of $6.90, trading at about $7.22/share. This suggests the stock has run to (and modestly exceeded) analysts’ consensus valuation level, with limited additional fundamental detail provided in the excerpt.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
